| Name | Title | Contact Details |
|---|---|---|
Andy Denison |
Chief Technology Officer | Profile |
One platform. Endless solutions.
The Legal Marketing Association (LMA) is a not-for-profit organization established in 1985, dedicated to supporting professionals in legal marketing, business development, client service, and communications. With over 4,200 members from 49 U.S. states and 28 countries, LMA serves a diverse community that includes in-house marketers, consultants, lawyers, and marketing students. The organization emphasizes ethical standards, thought leadership, and professional advocacy. LMA provides a range of professional development resources, including educational programs, networking opportunities, and publications. Its Body of Knowledge (BoK) framework defines essential skills for legal marketers, while various events and webinars promote knowledge sharing and innovation. LMA fosters a collaborative environment where members can connect, share best practices, and advance their careers in the evolving landscape of legal marketing.
Somos seu parceiro nos negócios! Toda as ferramentas de uma conta 100% digital, além de toda a segurança para realizar as operações do dia a dia com agilidade. Vem ser OneBank !
Tremont Strategies Group is a full service government affairs consulting firm offering a wide range of practices and committed to offering the highest quality service to its clients. Our firm specializes in executing complex, multi-faceted campaigns by utilizing a comprehensive approach to engage stakeholders, policymakers and the general public in order to educate and advocate for our client`s position. With decades of experience in the public and private sectors, we offer in-depth analysis on policy matters and proposals before state and federal government. Our team provides the expertise and entrepreneurial creativity needed to build successful comprehensive public affairs strategies.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.